Prognostic value of minimal residual disease measured by fusion‐gene transcript in infants with KMT2A‐rearranged acute lymphoblastic leukaemia treated according to the MLL‐Baby protocol

Summary The prognostic value of minimal residual disease (MRD) measured by fusion‐gene transcript (FGT) detection was investigated in 76 infants (aged ≤1 year) with acute lymphoblastic leukaemia (ALL) with lysine methyltransferase 2A (KMT2A) rearrangements. Either at the end of induction or at later...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2021-06, Vol.193 (6), p.1151-1156
Main Authors: Tsaur, Grigory, Popov, Alexander, Riger, Tatiana, Kustanovich, Anatoly, Solodovnikov, Alexander, Shorikov, Egor, Demina, Anna, Verzhbitskaya, Tatiana, Streneva, Olga, Makarova, Olga, Lapotentova, Elena, Aleinikova, Olga, Miakova, Natalia, Boichenko, Elmira, Kondratchik, Konstantin, Ponomareva, Natalia, Karachunskiy, Alexander, Roumiantsev, Alexander, Fechina, Larisa
Format: Article
Language:English
Subjects:
acute lymphoblastic leukaemia
Acute lymphoblastic leukemia
Chemotherapy
fusion‐gene transcripts
Hematology
Infants
KMT2A
Leukemia
Lysine
Methyltransferase
Minimal residual disease
Transcription
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary The prognostic value of minimal residual disease (MRD) measured by fusion‐gene transcript (FGT) detection was investigated in 76 infants (aged ≤1 year) with acute lymphoblastic leukaemia (ALL) with lysine methyltransferase 2A (KMT2A) rearrangements. Either at the end of induction or at later time‐points, FGT‐MRD‐positivity was associated with poor outcome. FGT‐MRD‐positivity after first consolidation or first high‐risk block detected 46·5% of infants with extremely poor outcome [disease‐free survival (SE) 0·06 (0·06), cumulative incidence of relapse (SE) 0·91 (0·05)], which was also confirmed in multivariable analysis. Thus, FGT‐MRD measurement at a single time‐point clearly identifies infants with ALL who are curable with conventional chemotherapy and those who would benefit only from other treatment approaches.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.17304